Hypha Labs (FUNI) 10-K 13 Jan 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2015	Jan. 12, 2016	Mar. 31, 2015
Document And Entity Information
Entity Registrant Name	DigiPath,Inc.
Entity Central Index Key	1,502,966
Document Type	10-K
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 5,755,922
Entity Common Stock, Shares Outstanding		15,129,372
Trading Symbol	DIGP
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Current assets:
Cash	$ 481,095	$ 5,102,620
Accounts receivable	6,146	123,045
Inventory	192,561	285,255
Prepaid expenses	60,447	81,770
Deposits	44,949	36,035
Total current assets	785,198	5,628,725
Fixed assets, net	1,373,691	$ 20,735
Available-for-sale securities	$ 14,000
Intangible assets		$ 28,336
Total Assets	$ 2,172,889	5,677,796
Current liabilities:
Accounts payable	62,383	125,854
Accrued expenses	21,671	25,910
Deferred revenues	73,121	39,133
Total current liabilities	157,175	190,897
Total Liabilities	157,175	190,897
Stockholders' Equity:
Series A convertible preferred stock, $0.001 par value, 10,000,000 shares authorized; 4,351,442 and 5,850,000 shares issued and outstanding at September 30, 2015 and 2014, respectively	4,351	5,850
Common stock, $0.001 par value, 90,000,000 shares authorized; 13,762,705 and 5,875,640 shares issued and outstanding at September 30, 2015 and 2014, respectively	13,763	5,876
Additional paid-in capital	10,224,551	$ 9,333,795
Accumulated other comprehensive loss	(36,000)
Accumulated (deficit)	(7,847,418)	$ (3,515,089)
Total digipath, Inc. Stockholders' Equity	2,359,247	5,830,432
Noncontrolling interest	(343,533)	(343,533)
Total Stockholders' Equity	2,015,714	5,486,899
Total Liabilities and Stockholders' Equity	$ 2,172,889	$ 5,677,796

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2015	May. 27, 2015	Sep. 30, 2014
Statement of Financial Position [Abstract]
Series A convertible preferred stock, par value	$ 0.001		$ 0.001
Series A convertible preferred stock, shares authorized	10,000,000		10,000,000
Series A convertible preferred stock, shares issued	4,351,442		5,850,000
Series A convertible preferred stock, shares outstanding	4,351,442		5,850,000
Common stock, par value	$ 0.001		$ 0.001
Common stock, shares authorized	90,000,000	900,000,000	90,000,000
Common stock, shares issued	13,762,705		5,875,640
Common stock, shares outstanding	13,762,705		5,875,640

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenues	$ 16,084	$ 54,941
Cost of sales	85,551	29,272
Gross profit (loss)	(69,467)	25,669
Operating expenses:
General and administrative	3,228,221	2,338,651
Research and development	143,766	23,125
Total operating expenses	3,371,987	2,361,776
Net operating loss	(3,441,454)	$ (2,336,107)
Other income (expense):
Other income	$ 36,000
Interest expense		$ (11,636)
Loss on disposal of fixed assets	$ (8,303)
Loss on impairment of intangible asset	(300,000)
Total other income (expense)	(272,303)	$ (11,636)
Net loss from continuing operations	(3,713,757)	(2,347,743)
Loss from operations of discontinued business component	(618,572)	(484,459)
Net loss	$ (4,332,329)	$ (2,832,202)
Weighted average number of common shares outstanding - basic and fully diluted	$ 9,906,468	$ 2,447,106
Net (loss) per share - basic and fully diluted	(0.37)	(0.96)
Net loss attributable to DigiPath, Inc. from continuing operations	$ (4,332,329)	$ (2,832,202)
Available-for-sale investments:
Change in net unrealized loss (net of tax effect)	(36,000)
Comprehensive loss	$ (4,368,329)	$ (2,832,202)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Non-Controlling Interest [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated (Deficit) [Member]	Total
Balance at Sep. 30, 2013		$ 554	$ 135,411			$ (682,887)	$ (546,922)
Balance, shares at Sep. 30, 2013		553,640
Common stock issued for services		$ 151	29,849				$ 30,000
Common stock issued for services, shares		151,000					25,000
Options exercised for cash		$ 1	3,299				$ 3,300
Options exercised for cash, shares		1,000					(1,000)
Common stock issued for cash		$ 4,420	2,205,580				$ 2,210,000
Common stock issued for cash, shares		4,420,000
Common stock options issued for services			10,377				10,377
Common stock options issued for services, shares
Preferred stock issued for cash	$ 6,000		5,994,000				6,000,000
Preferred stock issued for cash, shares	6,000,000
Vesting of previously issued common stock			268,813				268,813
Warrants in subsidiary issued for services			343,533				$ 343,533
Non-controlling interest in subsidiary			343,533	$ (343,533)
Conversion of preferred shares to common	$ (150)	$ 750	$ (600)
Conversion of preferred shares to common, shares	(150,000)	750,000
Net loss for the year ended						$ (2,832,202)	$ (2,832,202)
Balance at Sep. 30, 2014	$ 5,850	$ 5,876	$ 9,333,795	$ (343,533)		$ (3,515,089)	5,486,899
Balance, shares at Sep. 30, 2014	5,850,000	5,875,640
Common stock issued for services		$ 237	223,775				224,012
Common stock issued for services, shares		237,545
Options exercised for cash		$ 3	9,503				$ 9,506
Options exercised for cash, shares		2,881
Common stock options issued for services			663,626				$ 663,626
Conversion of preferred shares to common	$ (1,499)	$ 7,722	(6,223)
Conversion of preferred shares to common, shares	(1,498,558)	7,721,639
Cancellation of common stock		$ (75)	$ 75
Cancellation of common stock, shares		(75,000)
Unrealized loss on available-for-sale securities					$ (36,000)		$ (36,000)
Net loss for the year ended						$ (4,332,329)	(4,332,329)
Balance at Sep. 30, 2015	$ 4,351	$ 13,763	$ 10,224,551	$ (343,533)	$ (36,000)	$ (7,847,418)	$ 2,015,714
Balance, shares at Sep. 30, 2015	4,351,442	13,762,705

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (4,332,329)	$ (2,832,202)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debts expense	42,514
Depreciation and amortization expense	83,725	$ 4,586
Stock issued for services	224,012	298,813
Options and warrants granted for services	663,626	$ 353,911
Loss on disposal of fixed assets	8,303
Loss on impairment of development costs	28,336	$ 1,003,416
Loss on impairment of intangible asset	300,000
Decrease (increase) in assets:
Accounts receivable	74,385	$ (79,449)
Inventory	92,694	(126,292)
Prepaid expenses	21,323	(66,070)
Deposits	(8,914)	(36,035)
Increase (decrease) in liabilities:
Accounts payable	(63,471)	$ 95,967
Accrued expenses	$ (4,239)
Due to related party		$ (123,811)
Deferred revenues	$ 33,988	(189,815)
Net cash used in operating activities	$ (2,836,047)	(1,696,981)
Cash flows from investing activities
Purchase of development costs		(1,003,416)
Purchase of fixed assets	$ (1,444,984)	(28,336)
Purchase of intangible assets	(300,000)	$ (23,607)
Purchase of available-for-sale securities	(50,000)
Net cash used in investing activities	$ (1,794,984)	$ (1,055,359)
Cash flows from financing activities
Proceeds from revolving note due to related party		105,000
Repayment of revolving note due to related party		(98,703)
Proceeds from exercised options	$ 9,506	3,300
Proceeds from sale of preferred stock		5,600,000
Proceeds from sale of common stock		2,210,000
Net cash provided by financing activities	$ 9,506	7,819,597
Net increase (decrease) in cash	(4,621,525)	5,067,257
Cash - beginning	5,102,620	35,363
Cash - ending	$ 481,095	5,102,620
Supplemental disclosures:
Interest paid		$ 218
Income taxes paid
Non-cash investing and financing activities:
Note payable exchanged for preferred stock		$ 400,000
Value of preferred stock converted to common stock	$ 1,498,558

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Nature of Business and Significant Accounting Policies	Note 1 – Nature of Business and Significant Accounting Policies Nature of Business DigiPath, Inc. was incorporated in Nevada on October 5, 2010. DigiPath, Inc. and its subsidiaries (“DigiPath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our three business units as of September 30, 2015, which were all wholly-owned subsidiaries of DigiPath, Inc. as of such date, are described below. Ø DigiPath Labs, Inc Ø The National Marijuana News Corp Ø DigiPath Corp Stock Split All share and per share amounts herein have been given retroactive effect to the 1-for-10 reverse stock split of the Company’s common stock effected May 27, 2015 (See Note 12). Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2015: State of Abbreviated Name of Entity (1) Incorporation Relationship Reference DigiPath, Inc. (2) Nevada Parent DIGP DigiPath Labs, Inc. Nevada Subsidiary LABS TNM News, Inc. Nevada Subsidiary TNM GroSciences, Inc. (3) Colorado Subsidiary GRO DigiPath Corp. (4)(5) Nevada Subsidiary CORP (1) (2) (3) (4) (5) The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “DigiPath” or “DIGP”. The Company's headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein. Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments. Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments. Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of three months or less. The Company had no cash equivalents as of September 30, 2015 and 2014. Cash in Excess of FDIC Insured Limits The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 under current regulations. The Company had approximately $85,008 and $3,514,125 in excess of FDIC insured limits at September 30, 2015 and 2014, respectively. The Company has not experienced any losses in such accounts. Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $36,715 and $-0- as of September 30, 2015 and 2014, respectively. Inventory Inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out method. Inventory consists of digital slide scanners and slide scanner parts. Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 2-3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements 6 years Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. The Company recognized impairment losses on the disposal of fixed assets of $8,303 and $-0- during the years ended September 30, 2015 and 2014, respectively. Our intellectual property is comprised of indefinite-lived brand name acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company recognized an impairment loss on the carrying value of development costs of $28,336 and $1,003,416 for the years ended September 30, 2015 and 2014, respectively. Management believes these developed products will continue to be utilized by the Company to generate revenues; however, since the Company does not have historical operating experience, these amounts were written off. In addition, the Company recognized an impairment loss on the carrying value of its investment in TissueBLOX TM Marketable Securities The Company classifies its debt and marketable equity securities into held-to-maturity, trading, or available-for-sale categories. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders’ equity. Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. With respect to our cannabis lab testing revenues, we sell our services on a determinable fixed fee per test, or panel of tests basis, and offer a discounted price for customers that agree to enter into exclusive, long term contracts. We require payment prior to the delivery of results, as such, revenues are typically recognized upon the delivery of results upon completion of the tests. Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $145,293 and $103,219 for the years ended September 30, 2015 and 2014, respectively. Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2015 and 2014, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share. Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance. Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not. Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. Recent Accounting Pronouncements In September, 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-16, Business Combinations (Topic 805) In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In April 2015, the FASB issued ASU No. 2015-03, Interest–Imputation of Interest (Subtopic 835-30) In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) In June 2014, the FASB issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Going Concern

Going Concern	12 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	Note 2 – Going Concern As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of ($7,847,418), and as of September 30, 2015, the Company’s cash on hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fund short term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continue as a going concern. These financial statements also do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Discontinued Business Component

Discontinued Business Component	12 Months Ended
	Sep. 30, 2015
Discontinued Business Component
Discontinued Business Component	Note 3 – Discontinued Business Component The digital pathology business operating under the subsidiary DigiPath Corp. has been accounted for as a discontinued business component. The results of operations of this business have been removed from the results of continuing operations for all periods presented within our statements of operations. In October of 2015, DigiPath, Inc., divested approximately two-thirds of its ownership of DigiPath Corp. to warrant holders of DigiPath Corp. through the sale of common stock and the exercise of warrants, including warrants held by Steven D. Barbee, our former Director. Subsequent to the year ended September 30, 2015, our interest in DigiPath Corp. will be accounted for pursuant to the equity method of accounting due to our lack of control and reduced ownership percentage of approximately 33.3%. DigiPath Corp. continues to operate. However the change in accounting method for DigiPath, Inc. necessitates the deconsolidation of DigiPath Corp. be retrospectively presented as a discontinued business component. The operating results of the Digital Pathology business, which have been extracted and presented as “Loss from operations of discontinued business component” within the statements of operations, are summarized below: For the Years Ended September 30, 2015 2014 Revenues $ 395,718 $ 430,929 Cost of sales 360,652 268,257 Gross profit 35,066 162,672 Expenses: General and administrative 433,569 647,131 Research and development 220,432 - Total operating expenses 654,001 647,131 Net operating loss, net of tax (618,935 ) (484,459 ) Other income 363 - Net loss, net of tax $ (618,572 ) $ (484,459 )

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 4 – Related Party Transactions Options Issued to CFO for Services On June 19, 2015, the Company granted 100,000 common stock options as compensation for services to our new Chief Financial Officer. The options vest ratably in quarterly increments over one (1) year beginning September 19, 2015. The options are exercisable until June 19, 2025 at an exercise price of $0.33 per share. The estimated fair value using the Black-Scholes Pricing Model, based on a volatility rate of 237% and a call option value of $0.3274, was $32,744. The options are being expensed over the vesting period. The Company recognized $8,186 of stock based compensation expense during the year ended September 30, 2015. Stock Issued for Debt with Eric Stoppenhagen On April 9, 2014, pursuant to a series A convertible preferred stock purchase agreement (the “Series A SPA”), Mr. Stoppenhagen, who was then an affiliate of the Company, purchased 71,864 shares of the Issuer’s Series A Preferred Stock by way of a note payable for expenses converted on January 15, 2014 and 27,788 shares of the Issuer’s Series A Preferred Stock by way of a note payable for accounts payable converted on January 15, 2014 for an aggregate of 99,652 shares of the Issuer’s Series A Preferred Stock held by Mr. Stoppenhagen as a trustee of the Eric Paul Stoppenhagen Trust, dated September 30, 2013. On April 9, 2014, pursuant to a series A convertible preferred stock purchase agreement (the “Verdad Series A SPA”), Verdad Telecom, Inc. purchased 253,649 shares of the Issuer’s Series A Preferred Stock by way of a secured note payable and 46,699 shares of the Issuer’s Series A Preferred Stock by way of interest on a secured note payable through December 31, 2014 for an aggregate of 300,348 shares of the Issuer’s Series A Preferred Stock held by Verdad Telecom, Inc., of which Mr. Stoppenhagen owns 100% of the issued and outstanding stock. This note payable was satisfied in full by this exchange of company Series A Preferred Stock.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Note 5 – Fair Value of Financial Instruments Under FASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50 details the disclosures that are required for items measured at fair value. The Company has certain financial instruments that must be measured under the new fair value standard. The Company’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. The three levels are as follows: Level 1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the asset or liability. The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2015 and 2014, respectively: Fair Value Measurements at September 30, 2015 Level 1 Level 2 Level 3 Assets Cash $ 481,095 $ - $ - Available-for-sale securities 14,000 - - Total assets 495,095 - - Liabilities None - - - Total liabilities - - - $ 495,095 $ - $ - Fair Value Measurements at September 30, 2014 Level 1 Level 2 Level 3 Assets Cash $ 5,102,620 $ - $ - Intellectual properties - - 28,336 Total assets 5,102,620 - 28,336 Liabilities None - - - Total liabilities - - - $ 5,102,620 $ - $ 28,336 The fair value of our intellectual properties are deemed to approximate book value, and are considered Level 3 inputs as defined by ASC Topic 820-10-35. There were no transfers of financial assets or liabilities between Level 1, Level 2 and Level 3 inputs for the years ended September 30, 2015 or 2014. We recognized total impairment losses of $328,336 and $1,003,416 on our intellectual properties during the years ended September 30, 2015 and 2014, respectively.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Sep. 30, 2015
Receivables [Abstract]
Accounts Receivable	Note 6 – Accounts Receivable Accounts receivable was $6,146 and $123,045 at September 30, 2015 and 2014, respectively, net of allowance for uncollectible accounts of $36,715 and $-0- at September 30, 2015 and 2014, respectively.

Inventory

Inventory	12 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Note 7 – Inventory Inventory was $192,561 and $285,255 at September 30, 2015 and 2014, respectively. There is no allowance for inventory obsolescence. A total of $73,179 and $51,553 was written off due to obsolescence and included in the loss from operations of discontinued business component within the consolidated statements of operations during the years ended September 30, 2015 and 2014, respectively.

Fixed Assets

Fixed Assets	12 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Fixed Assets	Note 8 – Fixed Assets Fixed assets consist of the following at September 30, 2015 and 2014: For the Years Ended September 30, 2015 2014 Software $ 131,636 $ 10,019 Office equipment 35,467 - Furniture and fixtures 14,607 13,359 Lab equipment 835,006 35,420 Leasehold improvements 487,066 13,589 1,503,782 72,387 Less: accumulated depreciation (130,091 ) (51,652 ) Total $ 1,373,691 $ 20,735 During the year ended September 30, 2015, we realized a loss on the disposal of leasehold improvements in the amount of $8,303 when we terminated a lease whereby we had capitalized improvements with a historical cost basis of $13,586 and a net carrying value of $8,303 upon disposal. Depreciation and amortization expense totaled $83,725 and $4,586 for the years ended September 30, 2015 and 2014, respectively.

Available-for-Sale Securities

Available-for-Sale Securities	12 Months Ended
	Sep. 30, 2015
Schedule of Investments [Abstract]
Available-for-Sale Securities	Note 9 – Available-for-Sale Securities Available-for-sale securities consist of the following at September 30, 2015: Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Income Income Value Common stock $ 50,000 - $ (36,000 ) $ 14,000 Total available-for-sale securities $ 50,000 - $ (36,000 ) $ 14,000 Common stock consisted of a purchase of 400,000 shares of common stock acquired in March of 2015, in the amount of $50,000 in Blue Line Protection Group, Inc., a Nevada corporation. The Company had no investments in securities during the year ended September 30, 2014.

Intangible Assets

Intangible Assets	12 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 10 – Intangible Assets For the years ended September 30, 2015 and 2014, the Company determined that the carrying value of its intangible assets were impaired. As a result, we recognized losses on impairment of $328,336 and $1,003,416 during the years ended September 30, 2015 and 2014, respectively. The Company recognized an impairment loss on the carrying value of development costs of $28,336 and $1,003,416 for the years ended September 30, 2015 and 2014, respectively. Management believes these developed products will continue to be utilized by the Company to generate revenues; however, since the Company does not have historical operating experience, these amounts were written off. In addition, the Company recognized an impairment loss on the carrying value of its investment in TissueBLOX TM

Deferred Revenues

Deferred Revenues	12 Months Ended
	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenues	Note 11 – Deferred Revenues Deferred revenues consist of the following at September 30, 2015 and 2014, respectively. For the Years Ended September 30, 2015 2014 Unearned advertising revenue $ 4,167 $ - Unearned software support 68,954 39,133 Total $ 73,121 $ 39,133

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity	Note 12 – Stockholders’ Equity Reverse Stock Split On May 27, 2015, the Company effected a 1-for-10 reverse stock split (the “Reverse Stock Split”). No fractional shares were issued, and no cash or other consideration was paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split common stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. The Company was authorized to issue 900,000,000 shares of common stock prior to the Reverse Stock Split. As a result of the Reverse Stock Split, the Company’s authorized shares decreased ratably to 90,000,000 shares of common stock. The Reverse Stock Split did not have any effect on the stated par value of the common stock, or the Company’s authorized preferred stock. Unless otherwise stated, all share and per share information in this Annual Report on Form 10-K has been retroactively adjusted to reflect the Reverse Stock Split. Preferred Stock The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 6,000,000 have been designated as Series A Convertible Preferred Stock (“Series A Preferred”). As of September 30, 2015, there are 4,351,442 shares of Series A Preferred issued and outstanding. The Board of Directors is authorized to determine any number of series into which shares of preferred stock may be divided and to determine the rights, preferences, privileges and restrictions granted to any series of the preferred stock. Effective as of April 4, 2014, the designations, rights and preferences of the preferred shares changed to blank check preferred. On April 9, 2014, the Company entered into Securities Purchase Agreements with accredited investors pursuant to which the Company issued an aggregates of 6,000,000 shares of Series A Preferred in exchange for $6,000,000, which consisted of cash paid by investors and the cancellation of indebtedness of the Company under advances previously made to the Company by such investors. Shares of Series A Preferred were initially convertible into common stock based on a conversion formula equal to the price per share ($1.00) divided by a conversion price equal to the lesser of (A) $0.02 and (B) seventy percent (70%) of the average of the three (3) lowest daily volume weighted average prices (“VWAPs”) occurring during the twenty (20) consecutive trading days immediately preceding the applicable conversion date on which the Holder elects to convert any shares of Series A Preferred. On March 13, 2015, following the approval of our Board of Directors and the written consent of the holders of our Series A Preferred, the conversion price of the Series A Preferred was amended to remove the VWAP conversion feature from it, so that the Series A Preferred was convertible into common stock at a fixed price of $0.02 per share. As a result of the Reverse Stock Split, the conversion price of the Series A Preferred is currently $0.20 per share. The conversion price is adjustable in the event of stock splits and other adjustments in the Company’s capitalization, and in the event of certain negative actions undertaken by the Company. At the current conversion price, the 4,351,442 shares of Series A Preferred outstanding at September 30, 2015 are convertible into 21,757,210 shares of the common stock of the Company. No holder is permitted to convert its shares of Series A Preferred if such conversion would cause the holder to beneficially own more than 4.99% of the issued and outstanding common stock of the Company immediately after such conversion, unless waived by such holder by providing at least sixty-five days’ notice. Additional terms of the Series A Preferred include the following: ● The shares of Series A Preferred are entitled to dividends when, as and if declared by the Board as to the shares of the common stock of the Company into which such Series A Preferred may then be converted, subject to the 4.99% beneficial ownership limitation described above. ● Upon the liquidation or dissolution of the Company, or any merger or sale of all or substantially all of the assets, the shares of Series A Preferred are entitled to receive, prior to any distribution to the holders of common stock, 100% of the purchase price per share of Series A Preferred plus all accrued but unpaid dividends. ● The Series A Preferred plus all declared but unpaid dividends thereon automatically will be converted into common stock, at the then applicable conversion rate, upon the affirmative vote of the holders of a majority of the outstanding shares of Series A Preferred. ● Each share of Series A Preferred will carry a number of votes equal to the number of shares of common stock into which such Series A Preferred may then be converted, subject to the 4.99% beneficial ownership limitation described above. The Series A Preferred generally will vote together with the common stock and not as a separate class, except as provided below. ● Consent of the holders of the outstanding Series A Preferred is required in order for the Company to: (i) amend or change the rights, preferences, privileges or powers of, or the restrictions provided for the benefit of, the Series A Preferred; (ii) authorize, create or issue shares of any class of stock having rights, preferences, privileges or powers superior to the Series A Preferred; (iii) reclassify any outstanding shares into shares having rights, preferences, privileges or powers superior to the Series A Preferred; or (iv) amend the Company’s Articles of Incorporation or Bylaws in a manner that adversely affects the rights of the Series A Preferred. ● Pursuant to the Securities Purchase Agreements, holders of Series A Preferred are entitled to unlimited “piggyback” registration rights on registrations by the Company, subject to pro rata cutback at any underwriter’s discretion. Preferred Stock Conversions for the Year Ended September 30, 2015 For the year ended September 30, 2015, a total of 1,498,558 shares of Series A Preferred were converted into 7,721,685 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Preferred Stock Conversions for the Year Ended September 30, 2014 For the year ended September 30, 2014, a total of 150,000 shares of Series A Preferred were converted into 750,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Common Stock Common stock consists of $0.001 par value, 90,000,000 shares authorized, of which 13,762,705 shares were issued and outstanding as of September 30, 2015. Additional Common Stock Issuances for the Year Ended September 30, 2015 On August 10, 2015, the Company issued 25,000 shares of restricted common stock for professional services provided. The total fair value of the common stock was $5,887 based on the closing price of the Company’s common stock on the date of grant. During the quarter ended March 31, 2015, the Company issued 40,000 shares of common stock and cancelled 75,000 shares of common stock associated with transactions fully recorded in a previous period. During the same period, the Company issued 12,500 shares of common stock and recognized compensation expense associated with the issuance and vesting of these shares in the amount of $23,063. During the quarter ended December 31, 2014, the Company cancelled 1,219,589 non-plan options and issued 1,110,000 plan options and 500,000 warrants with exercise prices ranging from $0.30 to $0.85 per share, vesting immediately. The Company recorded the replacement of the stock options award as a modification of the terms of the cancelled awards, with the total compensation cost measured at the date of cancellation and replacement as being the sum of the portion of the grant-date fair value of the original award for which the requisite compensation expense had already been recognized at that date plus the incremental cost resulting from the cancellation and replacement. The Company recorded a net total of $845,540 stock option compensation expense related to these issuances and cancellations. During the quarter ended December 31, 2014, the Company issued 2,881 shares associated with the exercise of options with an exercise price of $3.30 per share and received $9,506 in cash. During the same period, the Company approved the issuance of 160,000 shares of the Company’s common stock and recognized $114,083 of compensation expense associated with the issuance and vesting of these shares, and additional compensation expense of $68,333 for the vesting of prior period awards. Common Stock Issuances for the Year Ended September 30, 2014 From July 1, 2011 to September 30, 2014, the Company issued 20,965 shares of its common stock for services received by an unrelated party. On May 14, 2014, the Company completed a private placement offering to certain accredited investors pursuant to which the Company sold an aggregate of 4,420,000 shares of the Company’s common stock resulting in gross proceeds of $2,210,000 to the Company. For the year ended September 30, 2014, the Company approved the issuance of 1,500,000 shares of the Company’s common stock. The Company recorded a stock compensation expense of $67,500 associated with these issuances for the vesting portion and $25,000 as issuance to the service providers. During the quarter ended June 30, 2014, the Company issued 1,000 shares associated with the exercise of 1,000 options at $3.30 and received $3,300 cash. During the year ended September 30, 2014, the Company approved the issuance of 105,500 shares of the Company’s common stock. The Company recorded a stock compensation expense of $92,788 associated with these issuances for the vesting portion plus a compensation expense of $101,188 for the vesting of prior period awards.

Common Stock Options

Common Stock Options	12 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Common Stock Options	Note 13 – Common Stock Options Stock Incentive Plan On March 5, 2012, we adopted our 2012 Stock Incentive Plan (the “2012 Plan”) providing for the issuance of up to 500,000 shares of common stock pursuant to the grant of options or other awards, including stock grants, to employees, officers or directors of, and consultants to, the Company and its subsidiaries. On May 20, 2014, the 2012 Plan was amended to increase the number of shares of Common Stock which may be issued pursuant to awards granted under the plan to 3,000,000. Options granted under the 2012 Plan may either be intended to qualify as incentive stock options under the Internal Revenue Code of 1986, or may be non-qualified options, and are exercisable over periods not exceeding ten years from date of grant. Common Stock Option Issuances for the Year Ended September 30, 2015 On June 19, 2015, the Company granted 100,000 common stock options as compensation for services to our new Chief Financial Officer. The options vest ratably in quarterly increments over one (1) year beginning September 19, 2015. The options are exercisable until June 19, 2025 at an exercise price of $0.33 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 237% and a call option value of $0.3274, was $32,744. The options are being expensed over the vesting period. The Company recognized $8,186 of stock based compensation expense during the year ended September 30, 2015. On June 1, 2015, the Company granted options to purchase 200,000 shares of common stock as compensation for services to our Chief Scientist. The options vest ratably in quarterly increments over two (2) years beginning September 1, 2015. The options are exercisable until June 1, 2025 at an exercise price of $0.40 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 247% and a call option value of $0.3978, was $79,552. The options are being expensed over the vesting period. The Company recognized $4,972 of stock based compensation expense on this option during the year ended September 30, 2015. During the quarter ended March 31, 2015, the Company did not issue any stock or option awards and recognized compensation expense associated with the vesting of option and stock awards issued in prior periods in the amount of $23,063. During the quarter ended December 31, 2014, the Company cancelled 1,219,589 non-plan options and issued 1,110,000 plan options and 500,000 warrants with exercise prices ranging from $0.40 to $0.85 per share, vesting immediately. The Company recorded the replacement of the stock options award as a modification of the terms of the cancelled awards, with the total compensation cost measured at the date of cancellation and replacement as being the sum of the portion of the grant-date fair value of the original award for which the requisite compensation expense had already been recognized at that date plus the incremental cost resulting from the cancellation and replacement. The Company recorded a net total of $845,540 stock option compensation expense related to these issuances and cancellations. Common Stock Options Exercised for the Year Ended September 30, 2015 On October 20, 2014, the Company issued 2,881 shares associated with the exercise of options with an exercise price of $3.30 per share and received $9,506 in cash. Common Stock Options Exercised for the Year Ended September 30, 2015 On December 31, 2014, the Company cancelled 300,000 unvested common stock options exercisable over a three year period from the original grant date of April 15, 2014 with an exercise price of $0.20 per share. On December 31, 2014, the Company cancelled 100,000 unvested common stock options exercisable over a three year period from the original grant date of June 1, 2014 with an exercise price of $0.50 per share. The following is a summary of information about the stock options outstanding at September 30, 2015. Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $0.33 – $3.30 1,413,881 3.82 years $ 0.43 1,163,881 $ 0.45 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2015 2014 Average risk-free interest rates 1.62 % 0.81 % Average expected life (in years) 4.49 3.00 Volatility 254 % 104 % The Black-Scholes option pricing model was developed for use in estimating the fair value of short-term traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including expected stock price volatility. Because the Company’s common stock options have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models do not necessarily provide a reliable single measure of the fair value of its common stock options. During the years ended September 30, 2015 and September 30, 2014, there were no options granted with an exercise price below the fair value of the underlying stock at the grant date. The weighted average fair value of options granted with exercise prices at the current fair value of the underlying stock during the years ended September 30, 2015 and 2014 was approximately $0.42 and $0.21 per option, respectively. The following is a summary of activity of outstanding common stock options: Weighted Average Number Exercise of Shares Price Balance, September 30, 2013 6,232 $ 3.30 Options expired - - Options cancelled - - Options granted 401,530 0.30 Options exercised (1,000 ) (3.30 ) Balance, September 30, 2014 406,762 0.30 Options expired (402,881 ) (0.30 ) Options cancelled - - Options granted 1,410,000 0.43 Options exercised - - Balance, September 30, 2015 1,413,881 $ 0.43 Exercisable, September 30, 2015 1,163,881 $ 0.45 The Company expensed $663,626 and $49,325 from the amortization of common stock options during the years ended September 30, 2015 and 2014, respectively. As of September 30, 2015, these options in the aggregate had no intrinsic value as the per share market price of $0.20 of the Company’s common stock as of such date was less than the weighted-average exercise price of these options of $0.43. Non-Plan Options During the three month period ended December 31, 2014, the Company issued options outside of the 2012 Plan to purchase 100,000 shares of common stock with an exercise price of $0.85, vesting quarterly over a period of one year, resulting in compensation expense of $82,826. These options were cancelled and re-issued as options under our 2012 plan in the quarter ended December 31, 2015. In addition to options granted under the 2012 Plan, at December 31, 2014, the Company had outstanding options to purchase 200,000 shares of common stock. During the three month period ended December 31, 2014, holders of non-plan options to purchase 200,000 shares of common stock surrendered such options to the Company for cancellation.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Common Stock Warrants	Note 14 – Common Stock Warrants Common Stock Warrants On December 31, 2014, the Company issued fully vested warrants to purchase 200,000 shares of common stock at an exercise price of $0.30 per share over three years to a service provider following the return for cancellation of prior stock grants and options totaling 200,000 shares. On December 30, 2014, the Company issued fully vested warrants to purchase 300,000 shares of common stock at an exercise price of $0.40 per share over three years to a former employee following the return for cancellation of prior stock grants and options totaling 300,000 shares. The following is a summary of information about the Common Stock Warrants outstanding at September 30, 2015. Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $0.30 – $0.40 500,000 2.25 years $ 0.36 500,000 $ 0.36 The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2015 2014 Average risk-free interest rates 1.64 % - % Average expected life (in years) 3.00 - Volatility 257 % - % The weighted average fair value of warrants granted with exercise prices at the current fair value of the underlying stock during the year ended September 30, 2015 was approximately $0.36 per warrant. The following is a summary of activity of outstanding common stock warrants: Weighted Average Number Exercise of Shares Price Balance, September 30, 2013 - $ - Warrants expired - - Warrants cancelled - - Warrants granted - - Warrants exercised - - Balance, September 30, 2014 - - Warrants expired - - Warrants cancelled - - Warrants granted 500,000 0.36 Warrants exercised - - Balance, September 30, 2015 500,000 $ 0.36 Exercisable, September 30, 2015 500,000 $ 0.36 Subsidiary Warrants On April 19, 2014, DigiPath Corp., a subsidiary of DigiPath, Inc. which is dedicated to digital microscopy, granted five-year common stock Purchase Warrants to Steven Barbee and Eric Stoppenhagen (the “Consultants”) to purchase an aggregate of 6,000,000 shares of common stock of DigiPath Corp. at an exercise price of $0.10 per share over a five (5) year period from the date of grant. The Company recorded a total of $343,533 of expense associated with the issuance of these warrants and recorded a non-controlling interest as a reduction to total stockholder’s equity on the Company’s balance sheet because the warrants were issued by the Company’s subsidiary. No continued allocation of the non-controlling interest in the equity of the subsidiary has been recognized, as the warrants hadn’t been exercised and DigiPath, Inc. was still in control of 100% of the interests of the subsidiary as of September 30, 2015. The Company recorded a total of total of $343,533 expense associated with warrants and recorded as a non-controlling interest because the warrants are issued by the subsidiary. As a result of the Company’s divestiture of DigiPath Corp. as described in Note 18, these warrants are no longer outstanding.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Lease Commitment The Company leases space for its lab operations in Las Vegas, Nevada. Amounts of minimum future annual commitments, including common area maintenance fees, under non-cancelable operating leases are as follows: 2016 $ 24,028 2017 196,673 2018 204,540 2019 212,722 2020 388,015 Total $ 1,025,978 In addition to this commitment, the Company pays monthly rent in the aggregate amount of $2,616 for potential lab space, which is rented on a month-to-month basis. Rent expense was $228,616 and $63,974 for the years ended September 30, 2015 and 2014, respectively.

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax	Note 16 – Income Tax The Company accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes, referred to as temporary differences. For the years ended September 30, 2015 and 2014, the Company incurred a net operating loss and, accordingly, no provision for income taxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization of any tax assets. At September 30, 2015, the Company had approximately $6,652,500 of federal net operating losses. The net operating loss carry forwards, if not utilized, will begin to expire in 2031. The effective income tax rate for the years ended September 30, 2015 and 2014 consisted of the following: September 30, 2015 2014 Federal statutory income tax rate 35.00 % 34.00 % State income taxes 3.95 % 6.90 % Change in valuation allowance (38.95 )% (40.90 )% Net effective income tax rate - - The components of the Company’s deferred tax asset are as follows: September 30, 2015 2014 Deferred tax assets: Net operating loss carry forwards $ 2,328,375 $ 1,433,582 Net deferred tax assets before valuation allowance $ 2,328,375 $ 1,433,582 Less: Valuation allowance (2,328,375 ) (1,433,582 ) Net deferred tax assets $ - $ - Based on the available objective evidence, including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assets at September 30, 2015 and 2014, respectively. In accordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

Segment Operating Results

Segment Operating Results	12 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Operating Results	Note 17 – Segment Operating Results Our business is comprised of two general divisions: cannabis related and digital pathology (microscopy) sales and services. The following table shows operating results for these two divisions for the years ended September 30, 2015 and 2014. The microscopy segment has been extracted and presented as “Loss from operations of discontinued business component” within the statements of operations pursuant to a subsequent divestiture. For the years ended September 30, 2015 2014 Cannabis Microscopy Cannabis Microscopy Revenues $ 16,084 $ 395,718 $ - $ 485,870 Cost of sales 85,551 360,652 - 297,529 Gross profit (loss) (69,467 ) 35,066 - 188,341 Operating expenses (3,371,070 ) (654,001 ) (2,323,899 ) (685,008 ) Loss from operations (3,440,537 ) (618,935 ) (2,323,899 ) (496,667 ) Other income (expense) (273,220 ) 363 - (11,636 ) Net loss $ (3,713,757 ) $ (618,572 ) $ (2,323,899 ) $ (508,303 ) The following table shows net assets for these two divisions, along with the corporate holding company, as of September 30, 2015 and 2014. September 30, 2015 September 30, 2014 Corporate Cannabis Microscopy Corporate Cannabis Microscopy Net assets $ 362,513 $ 1,470,902 $ 182,299 $ 3,907,777 $ 1,017,680 $ 561,442

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 18 – Subsequent Events Appointment of Chairman of Board of Directors On October 7, 2015, we appointed Joseph Bianco to chair our Board of Directors. On November 23, 2015, we entered into an agreement with our Chairman of the Board for an initial term of 15 months, commencing retroactively from October 1, 2015 and ending on December 31, 2016, in which Mr. Bianco will be entitled to a monthly fee of $4,000, of which $2,000 shall be deferred until the Company’s operations become cash flow positive. Also, commencing on January 1, 2016, if no notice of cancellation has been issued prior thereto, Mr. Bianco shall be awarded 500,000 shares of common stock for each calendar year of service, subject to a ratable “claw back” provision. As of the date of this filing, the shares have not yet been issued. Preferred Stock Conversions On October 29, 2015, a shareholder converted 100,000 shares of Series A Preferred into 500,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. On October 8, 2015, a shareholder converted 120,000 shares of Series A Preferred into 600,000 shares of common stock. The stock was converted in accordance with the conversion terms; therefore no gain or loss has been recognized. Preferred Stock Cancellation On October 1, 2015, a shareholder cancelled 60,000 shares of Series A Preferred as part of the divestiture of DigiPath Corp., as more fully explained below. Common Stock Sales On December 21, 2015, the Company sold 166,667 units, consisting of 166,667 shares of its common stock and an equal number of warrants, exercisable at $0.30 per share over a thirty six month period, in exchange for total proceeds of $25,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. On November 23, 2015, the Company sold 100,000 units, consisting of 100,000 shares of its common stock and an equal number of warrants, exercisable at $0.40 per share over a thirty six month period, in exchange for total proceeds of $20,000. The proceeds received were allocated between the common stock and warrants on a relative fair value basis. Common Stock Options Issued for Services On November 20, 2015, the Company granted 500,000 fully vested common stock options as compensation for services to a consultant. The options are exercisable over a three year period at an exercise price of $0.181 per share. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 234% and a call option value of $0.1734, was $86,708. Divestiture of Wholly-Owned Subsidiary, DigiPath Corp. On October 1, 2015, DigiPath, Inc., entered into an Omnibus Agreement and Amendment (the “Agreement”) with DigiPath Corp., and our former Director, Steven D. Barbee. Pursuant to the Agreement, among other things: ● The exercise price of the warrant held by Mr. Barbee to purchase 3,000,000 shares of common stock of DigiPath Corp. (the “Barbee Warrant”) was reduced from $0.10 per share to $0.0333333 per share, and Mr. Barbee subsequently exercised the warrant. ● Mr. Barbee resigned as a director of the Company. ● The Consulting, Confidentiality and Proprietary Rights Agreement, dated as of May 30, 2014, between the Company and Mr. Barbee, as amended, was terminated. ● Indebtedness of approximately $18,000 owed by the Company to DigiPath Corp. was cancelled. ● DigiPath Corp. was provided with the right to require the Company to change its name so as not to include the name “DigiPath” in the event of the sale of all or substantially all of the assets or capital stock of DigiPath Corp., or a merger of DigiPath Corp. following which the Company ceases to be a shareholder of DigiPath Corp., in each case, that occurs within 12 months following the date of the Agreement. ● The Company, as a shareholder of DigiPath Corp, was provided with (i) rights of first-refusal and co-sale rights with respect to sales of common stock of DigiPath Corp by Barbee, and (ii) pre-emptive rights with respect to issuances of common stock by DigiPath Corp. Concurrently with the execution of the Agreement, DigiPath Corp. agreed to issue 3,000,000 shares of its common stock to a third party for an aggregate purchase price of $100,000, and an affiliate of such party agreed to surrender 60,000 shares of Series A Preferred of the Company for cancellation, and terminate a previously held warrant to purchase 3,000,000 shares of common stock of DigiPath Corp. As a result of such issuance of shares of DigiPath Corp common stock, and after giving effect to the exercise of the Barbee Warrant, the Company continued to hold approximately 34% of the outstanding shares of common stock of DigiPath Corp. Following the execution of the Agreement, Mr. Barbee continued to serve as the President and sole director of DigiPath Corp.

Nature of Business and Signif25

Nature of Business and Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Nature of Business	Nature of Business DigiPath, Inc. was incorporated in Nevada on October 5, 2010. DigiPath, Inc. and its subsidiaries (“DigiPath,” the “Company,” “we,” “our” or “us”) supports the cannabis industry’s best practices for reliable testing, cannabis education and training, and brings unbiased cannabis news coverage to the cannabis industry. Our three business units as of September 30, 2015, which were all wholly-owned subsidiaries of DigiPath, Inc. as of such date, are described below. Ø DigiPath Labs, Inc Ø The National Marijuana News Corp Ø DigiPath Corp
Stock Split	Stock Split All share and per share amounts herein have been given retroactive effect to the 1-for-10 reverse stock split of the Company’s common stock effected May 27, 2015 (See Note 12).
Basis of Accounting	Basis of Accounting The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All references to Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification (“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2015: State of Abbreviated Name of Entity (1) Incorporation Relationship Reference DigiPath, Inc. (2) Nevada Parent DIGP DigiPath Labs, Inc. Nevada Subsidiary LABS TNM News, Inc. Nevada Subsidiary TNM GroSciences, Inc. (3) Colorado Subsidiary GRO DigiPath Corp. (4)(5) Nevada Subsidiary CORP (1) (2) (3) (4) (5) The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein as the “Company”, “DigiPath” or “DIGP”. The Company's headquarters are located in Las Vegas, Nevada and substantially all of its customers are within the United States. These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings, financial position or cash flows.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Segment Reporting	Segment Reporting ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has two reportable segments.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company adopted ASC 820, Fair Value Measurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows: - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. The carrying value of cash, accounts receivable, accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short term nature of the instruments.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of three months or less. The Company had no cash equivalents as of September 30, 2015 and 2014.
Cash in Excess of FDIC Insured Limits	Cash in Excess of FDIC Insured Limits The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (FDIC) up to $250,000 under current regulations. The Company had approximately $85,008 and $3,514,125 in excess of FDIC insured limits at September 30, 2015 and 2014, respectively. The Company has not experienced any losses in such accounts.
Accounts Receivable	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. The Company had an allowance for doubtful accounts of $36,715 and $-0- as of September 30, 2015 and 2014, respectively.
Inventory	Inventory Inventory is valued at the lower of cost or market. Cost is determined on a first-in, first-out method. Inventory consists of digital slide scanners and slide scanner parts.
Fixed Assets	Fixed Assets Fixed assets are stated at the lower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-line method based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy: Software 2-3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements 6 years Repairs and maintenance expenditures are charged to operations as incurred. Major improvements and replacements, which have extend the useful life of an asset, are capitalized and depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulated depreciation and amortization are eliminated and any resulting gain or loss is reflected in operations.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may not be recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and current projections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating results based upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carrying value exceeds discounted cash flows of future operations. The Company recognized impairment losses on the disposal of fixed assets of $8,303 and $-0- during the years ended September 30, 2015 and 2014, respectively. Our intellectual property is comprised of indefinite-lived brand name acquired and have been assigned an indefinite life as we currently anticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company recognized an impairment loss on the carrying value of development costs of $28,336 and $1,003,416 for the years ended September 30, 2015 and 2014, respectively. Management believes these developed products will continue to be utilized by the Company to generate revenues; however, since the Company does not have historical operating experience, these amounts were written off. In addition, the Company recognized an impairment loss on the carrying value of its investment in TissueBLOX TM
Marketable Securities	Marketable Securities The Company classifies its debt and marketable equity securities into held-to-maturity, trading, or available-for-sale categories. Debt securities are classified as held-to-maturity when the Company has the positive intent and ability to hold the securities to maturity. Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale. Held-to-maturity securities are recorded as either short-term or long-term on the balance sheet based on contractual maturity date and are stated at amortized cost. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Debt and marketable equity securities not classified as held-to-maturity or as trading are classified as available-for-sale and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders’ equity.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC 605, Revenue Recognition. ASC 605 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery of product has met the criteria established in the arrangement or services rendered; (3) the fee is fixed and determinable; and (4) collectability is reasonably assured. This occurs when the products or services are completed in accordance with the contracts we have with clients. In connection with our products and services arrangements, when we are paid in advance, these amounts are classified as deferred revenue and amortized over the term of the agreement. With respect to our cannabis lab testing revenues, we sell our services on a determinable fixed fee per test, or panel of tests basis, and offer a discounted price for customers that agree to enter into exclusive, long term contracts. We require payment prior to the delivery of results, as such, revenues are typically recognized upon the delivery of results upon completion of the tests.
Advertising Costs	Advertising Costs The Company expenses the cost of advertising and promotions as incurred. Advertising and promotions expense was $145,293 and $103,219 for the years ended September 30, 2015 and 2014, respectively.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended September 30, 2015 and 2014, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 505-50 (ASC 505-50). All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.
Income Taxes	Income Taxes The Company recognizes deferred tax assets and liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enacted tax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides a valuation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.
Uncertain Tax Positions	Uncertain Tax Positions In accordance with ASC 740, “Income Taxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technical merits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities. The assessment of the Company’s tax position relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions. Various taxing authorities periodically audit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions, including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposures connected with these various tax filing positions, including state and local taxes, the Company records allowances for probable exposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited and fully resolved. The Company has not yet undergone an examination by any taxing authorities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In September, 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-16, Business Combinations (Topic 805) In August, 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date In April 2015, the FASB issued ASU No. 2015-03, Interest–Imputation of Interest (Subtopic 835-30) In August, 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) In June 2014, the FASB issued ASU No. 2014-12, Compensation – Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers There are no other recently issued accounting pronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, results of operations, or cash flows.

Nature of Business and Signif26

Nature of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Schedule of Entities Under Common Control and Ownership	The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at September 30, 2015: State of Abbreviated Name of Entity (1) Incorporation Relationship Reference DigiPath, Inc. (2) Nevada Parent DIGP DigiPath Labs, Inc. Nevada Subsidiary LABS TNM News, Inc. Nevada Subsidiary TNM GroSciences, Inc. (3) Colorado Subsidiary GRO DigiPath Corp. (4)(5) Nevada Subsidiary CORP (1) (2) (3) (4) (5)
Schedule of Estimated Useful Lives of Fixed Assets Property, Plant and Equipment	Software 2-3 years Office equipment 5 years Furniture and fixtures 5 years Lab equipment 7 years Leasehold improvements 6 years

Discontinued Business Compone27

Discontinued Business Component (Tables)	12 Months Ended
	Sep. 30, 2015
Discontinued Business Component Tables
Schedule of Discontinued Business Component	The operating results of the Digital Pathology business, which have been extracted and presented as “Loss from operations of discontinued business component” within the statements of operations, are summarized below: For the Years Ended September 30, 2015 2014 Revenues $ 395,718 $ 430,929 Cost of sales 360,652 268,257 Gross profit 35,066 162,672 Expenses: General and administrative 433,569 647,131 Research and development 220,432 - Total operating expenses 654,001 647,131 Net operating loss, net of tax (618,935 ) (484,459 ) Other income 363 - Net loss, net of tax $ (618,572 ) $ (484,459 )

Fair Value of Financial Instr28

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Financial Instruments at Fair Value on Recurring Basic	The following schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balance sheets as of September 30, 2015 and 2014, respectively: Fair Value Measurements at September 30, 2015 Level 1 Level 2 Level 3 Assets Cash $ 481,095 $ - $ - Available-for-sale securities 14,000 - - Total assets 495,095 - - Liabilities None - - - Total liabilities - - - $ 495,095 $ - $ - Fair Value Measurements at September 30, 2014 Level 1 Level 2 Level 3 Assets Cash $ 5,102,620 $ - $ - Intellectual properties - - 28,336 Total assets 5,102,620 - 28,336 Liabilities None - - - Total liabilities - - - $ 5,102,620 $ - $ 28,336

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Schedule of Fixed Assets	Fixed assets consist of the following at September 30, 2015 and 2014: For the Years Ended September 30, 2015 2014 Software $ 131,636 $ 10,019 Office equipment 35,467 - Furniture and fixtures 14,607 13,359 Lab equipment 835,006 35,420 Leasehold improvements 487,066 13,589 1,503,782 72,387 Less: accumulated depreciation (130,091 ) (51,652 ) Total $ 1,373,691 $ 20,735

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	12 Months Ended
	Sep. 30, 2015
Schedule of Investments [Abstract]
Schedule of Available-for-Sale Securities	Available-for-sale securities consist of the following at September 30, 2015: Gains in Losses in Accumulated Accumulated Other Other Estimated Amortized Comprehensive Comprehensive Fair Cost Income Income Value Common stock $ 50,000 - $ (36,000 ) $ 14,000 Total available-for-sale securities $ 50,000 - $ (36,000 ) $ 14,000

Deferred Revenues (Tables)

Deferred Revenues (Tables)	12 Months Ended
	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Schedule of Deferred Revenues	Deferred revenues consist of the following at September 30, 2015 and 2014, respectively. For the Years Ended September 30, 2015 2014 Unearned advertising revenue $ 4,167 $ - Unearned software support 68,954 39,133 Total $ 73,121 $ 39,133

Common Stock Options (Tables)

Common Stock Options (Tables)	12 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Common Stock Option Outstanding	The following is a summary of information about the stock options outstanding at September 30, 2015. Shares Underlying Shares Underlying Options Outstanding Options Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Options Contractual Exercise Options Exercise Prices Outstanding Life Price Exercisable Price $0.33 – $3.30 1,413,881 3.82 years $ 0.43 1,163,881 $ 0.45
Schedule of Option Pricing Model Weighted-average Assumptions Used for Grands Under Fixed Option Plan	The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2015 2014 Average risk-free interest rates 1.62 % 0.81 % Average expected life (in years) 4.49 3.00 Volatility 254 % 104 %
Summary of Common Stock Options Activity Outstanding	The following is a summary of activity of outstanding common stock options: Weighted Average Number Exercise of Shares Price Balance, September 30, 2013 6,232 $ 3.30 Options expired - - Options cancelled - - Options granted 401,530 0.30 Options exercised (1,000 ) (3.30 ) Balance, September 30, 2014 406,762 0.30 Options expired (402,881 ) (0.30 ) Options cancelled - - Options granted 1,410,000 0.43 Options exercised - - Balance, September 30, 2015 1,413,881 $ 0.43 Exercisable, September 30, 2015 1,163,881 $ 0.45

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Common Stock Warrants Outstanding	The following is a summary of information about the Common Stock Warrants outstanding at September 30, 2015. Shares Underlying Shares Underlying Warrants Outstanding Warrants Exercisable Weighted Shares Average Weighted Shares Weighted Range of Underlying Remaining Average Underlying Average Exercise Warrants Contractual Exercise Warrants Exercise Prices Outstanding Life Price Exercisable Price $0.30 – $0.40 500,000 2.25 years $ 0.36 500,000 $ 0.36
Schedule of Warrant Pricing Model Weighted-average Assumptions Used for Grands Under Fixed Option Plan	The fair value of each warrant grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions used for grants under the fixed option plan: September 30, September 30, 2015 2014 Average risk-free interest rates 1.64 % - % Average expected life (in years) 3.00 - Volatility 257 % - %
Summary of Common Stock Warrants Activity Outstanding	The following is a summary of activity of outstanding common stock warrants: Weighted Average Number Exercise of Shares Price Balance, September 30, 2013 - $ - Warrants expired - - Warrants cancelled - - Warrants granted - - Warrants exercised - - Balance, September 30, 2014 - - Warrants expired - - Warrants cancelled - - Warrants granted 500,000 0.36 Warrants exercised - - Balance, September 30, 2015 500,000 $ 0.36 Exercisable, September 30, 2015 500,000 $ 0.36

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payment Under Operating Leases	The Company leases space for its lab operations in Las Vegas, Nevada. Amounts of minimum future annual commitments, including common area maintenance fees, under non-cancelable operating leases are as follows: 2016 $ 24,028 2017 196,673 2018 204,540 2019 212,722 2020 388,015 Total $ 1,025,978

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The effective income tax rate for the years ended September 30, 2015 and 2014 consisted of the following: September 30, 2015 2014 Federal statutory income tax rate 35.00 % 34.00 % State income taxes 3.95 % 6.90 % Change in valuation allowance (38.95 )% (40.90 )% Net effective income tax rate - -
Schedule of Deferred Tax Asset	The components of the Company’s deferred tax asset are as follows: September 30, 2015 2014 Deferred tax assets: Net operating loss carry forwards $ 2,328,375 $ 1,433,582 Net deferred tax assets before valuation allowance $ 2,328,375 $ 1,433,582 Less: Valuation allowance (2,328,375 ) (1,433,582 ) Net deferred tax assets $ - $ -

Segment Operating Results (Tabl

Segment Operating Results (Tables)	12 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting	For the years ended September 30, 2015 2014 Cannabis Microscopy Cannabis Microscopy Revenues $ 16,084 $ 395,718 $ - $ 485,870 Cost of sales 85,551 360,652 - 297,529 Gross profit (loss) (69,467 ) 35,066 - 188,341 Operating expenses (3,371,070 ) (654,001 ) (2,323,899 ) (685,008 ) Loss from operations (3,440,537 ) (618,935 ) (2,323,899 ) (496,667 ) Other income (expense) (273,220 ) 363 - (11,636 ) Net loss $ (3,713,757 ) $ (618,572 ) $ (2,323,899 ) $ (508,303 )
Schedule of Segment Operating Results Net Assets	September 30, 2015 September 30, 2014 Corporate Cannabis Microscopy Corporate Cannabis Microscopy Net assets $ 362,513 $ 1,470,902 $ 182,299 $ 3,907,777 $ 1,017,680 $ 561,442

Nature of Business and Signif37

Nature of Business and Significant Accounting Policies (Details Narrative) - USD ($)	May. 27, 2015	Apr. 19, 2014	Sep. 30, 2015	Sep. 30, 2014
Accounting Policies [Abstract]
Own minority interest		100.00%	33.34%
Reverse stock split	1-for-10 reverse stock split
Warrants issued to purchase common stock, shares		6,000,000
Percentage of ownership in non-controlling interest upon exercise of stock		66.67%
Percentage of ownership in non-controlling interest upon dilution		33.33%
Fair value of the warrants in non-controlling interest		$ 343,533
Cash equivalents
Federal Deposit Insurance Corporation			$ 250,000
Exceeded insured amounts FDIC			85,008	$ 3,514,125
Allowance for doubtful accounts			36,715	0
Impairment of Long-Lived Assets			8,303	0
Loss on impairment of development costs			28,336	$ 1,003,416
Loss on impairment of intangible asset			300,000
Repay investment impaired			300,000
Advertising and promotions expense			$ 145,293	$ 103,219

Nature of Business and Signif38

Nature of Business and Significant Accounting Policies - Schedule of Entities Under Common Control and Ownership (Details) - Entities Under Common Control and Ownership [Member]	12 Months Ended
	Sep. 30, 2015
Name of Entity	DigiPath, Inc.	[1],[2]
State of Incorporation	Nevada
Relationship	Parent
Abbreviated Reference	DIGP
Name of Entity	DigiPath Labs, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Abbreviated Reference	LABS
Name of Entity	TNM News, Inc.	[1]
State of Incorporation	Nevada
Relationship	Subsidiary
Abbreviated Reference	TNM
Name of Entity	GroSciences, Inc.	[1],[3]
State of Incorporation	Colorado
Relationship	Subsidiary
Abbreviated Reference	GRO
Name of Entity	DigiPath Corp.	[1],[4],[5]
State of Incorporation	Nevada
Relationship	Subsidiary
Abbreviated Reference	CORP
[1]	All entities are in the form of a corporation.
[2]	Holding company, which owns each of the wholly-owned subsidiaries. As of September 30, 2015, all subsidiaries were wholly-owned by the holding company.
[3]	Entity formed for prospective purposes, but has not incurred any income or expenses to date.
[4]	On April 19, 2014, DigiPath Corp. issued warrants to purchase an aggregate 6,000,000 shares of common stock, which, if exercised in total would represent approximately two thirds (66.67%) of the equity of the subsidiary, resulting in dilution of DigiPath, Inc.’s. ownership to approximately one third (33.33%). The fair value of the warrants resulted in a non-controlling interest of $343,533, which was recorded as a reduction to total stockholder's equity on the Company's balance sheet. No continued allocation of the non-controlling interest in the equity of the subsidiary had been recognized through September 30, 2015, as the warrants hadn't been exercised and DigiPath, Inc. was still in control of 100% of the interests of the subsidiary.
[5]	On October 1, 2015, subsequent to the periods presented in these financial statements, we divested two-thirds of this entity through the exercise of warrants and sale of new issuances. We now own a minority interest of 33.34%. The historical income and loss of the deconsolidated entity have been retroactively presented as a discontinued business component in the financial statements herein.

Nature of Business and Signif39

Nature of Business and Significant Accounting Policies - Schedule of Estimated Useful Lives of Fixed Assets Property, Plant and Equipment (Details)	12 Months Ended
	Sep. 30, 2015
Software [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	2 years
Software [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	3 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	5 years
Furniture And Fixtures [Member]
Property, Plant and Equipment, Useful Life	5 years
Lab Equipment [Member]
Property, Plant and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	6 years

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ (7,847,418)	$ (3,515,089)

Discontinued Business Compone41

Discontinued Business Component (Details Narrative)	Sep. 30, 2015	Apr. 19, 2014
Own minority interest	33.34%	100.00%
DigiPath Corp [Member]
Own minority interest	33.30%

Discontinued Business Compone42

Discontinued Business Component - Schedule of Discontinued Business Component (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Discontinued Business Component - Schedule Of Discontinued Business Component Details
Revenues	$ 395,718	$ 430,929
Cost of sales	360,652	268,257
Gross profit	35,066	162,672
General and administrative	433,569	$ 647,131
Research and development	220,432
Total operating expenses	654,001	$ 647,131
Net operating loss, net of tax	(618,935)	$ (484,459)
Other income	363
Net loss, net of tax	$ (618,572)	$ (484,459)

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jun. 19, 2015	Jun. 01, 2015	May. 14, 2014	Apr. 09, 2014	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Apr. 19, 2014
Company granted stock options as compensation for services								25,000
Exercise price							$ 0.45
Volatility rate	237.00%	247.00%					254.00%	104.00%
Stock based compensation expense	$ 8,186	$ 4,972				$ 845,540
Issuance of common stock, shares			4,420,000		40,000
Own minority interest							33.34%		100.00%
Common Stock [Member] | Chief Financial Officer [Member]
Company granted stock options as compensation for services	100,000
Options exercisable term	until June 19, 2025
Exercise price	$ 0.33
Volatility rate	237.00%
Call option value	$ 0.3274
Stock option vlaue	$ 32,744
Stock based compensation expense							$ 8,186
Series A Convertible Preferred Stock [Member] | Eric Stoppenhagen [Member]
Stock issued for debt				27,788
Stock issued during period, shares settlement				99,652
Series A Convertible Preferred Stock [Member] | Verdad Telecom, Inc [Member]
Stock issued for debt				253,649
Series A Convertible Preferred Stock [Member] | Verdad Telecom, Inc [Member] | December 31, 2014 [Member]
Stock issued for debt				46,699
Stock issued during period, shares settlement				300,348
Series A Convertible Preferred Stock [Member] | Mr. Stoppenhagen [Member]
Own minority interest				100.00%
Series A Convertible Preferred Stock [Member] | Mr. Stoppenhagen [Member]
Stock issued for debt				71,864

Fair Value of Financial Instr44

Fair Value of Financial Instruments (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fair Value Disclosures [Abstract]
Impairment losses	$ 328,336	$ 1,003,416

Fair Value of Financial Instr45

Fair Value of Financial Instruments - Summary of Financial Instruments at Fair Value on Recurring Basic (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Level 1 [Member]
Cash	$ 481,095	$ 5,102,620
Available-for-sale securities	14,000
Intellectual properties
Assets	$ 495,095	$ 5,102,620
Total liabilities
Total	$ 495,095	$ 5,102,620
Level 2 [Member]
Cash
Available-for-sale securities
Intellectual properties
Assets
Total liabilities
Total
Level 3 [Member]
Cash
Available-for-sale securities
Intellectual properties		$ 28,336
Assets		$ 28,336
Total liabilities
Total		$ 28,336

Accounts Receivable (Details Na

Accounts Receivable (Details Narrative) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Receivables [Abstract]
Accounts receivable	$ 6,146	$ 123,045
Allowance for uncollectible accounts, net	$ 36,715	$ 0

Inventory (Details Narrative)

Inventory (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Inventory Disclosure [Abstract]
Inventory	$ 192,561	$ 285,255
Inventory written off	$ 73,179	$ 51,553

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Fixed Assets Details Narrative
Loss on the disposal of leasehold improvements	$ 8,303
Lease capitalized improvements cost	13,586
Disposal of fixed assets	8,303
Depreciation and amortization expense	$ 83,725	$ 4,586

Fixed Assets - Schedule of Fixe

Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Property, Plant and Equipment [Abstract]
Software	$ 131,636	$ 10,019
Office equipment	35,467
Furniture and fixtures	14,607	$ 13,359
Lab equipment	835,006	35,420
Leasehold improvements	487,066	13,589
Fixed Assets, Gross	1,503,782	72,387
Less: accumulated depreciation	(130,091)	(51,652)
Total	$ 1,373,691	$ 20,735

Available-for-Sale Securities50

Available-for-Sale Securities (Details Narrative) - USD ($)	May. 14, 2014	Mar. 31, 2015	Mar. 31, 2015
Issuance of common stock, shares	4,420,000		40,000
Blue Line Protection Group, Inc [Member]
Issuance of common stock, shares		400,000
Issuance of common stock, amount		$ 50,000

Available-for-Sale Securities -

Available-for-Sale Securities - Schedule of Available-for-Sale Securities (Details)	Sep. 30, 2015USD ($)
Amortized Cost [Member]
Common stock	$ 50,000
Total available-for-sale securities	$ 50,000
Gains In Accumulated Other Comprehensive Income [Member]
Common stock
Total available-for-sale securities
Losses In Accumulated Other Comprehensive Income [Member]
Common stock	$ (36,000)
Total available-for-sale securities	(36,000)
Estimated Fair Value [Member]
Common stock	14,000
Total available-for-sale securities	$ 14,000

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Intangible Assets Details Narrative
Losses on impairment	$ 328,336	$ 1,003,416
Loss on impairment of development costs	28,336	$ 1,003,416
Loss on impairment of intangible asset	300,000
Repay investment impaired	$ 300,000

Deferred Revenues - Schedule of

Deferred Revenues - Schedule of Deferred Revenues (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Deferred Revenue	$ 73,121	$ 39,133
Unearned Advertising Revenue [Member]
Deferred Revenue	4,167
Unrecognized Software Support [Member]
Deferred Revenue	$ 68,954	$ 39,133

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Aug. 10, 2015	Jun. 19, 2015	Jun. 01, 2015	May. 27, 2015	Mar. 13, 2015	Oct. 20, 2014	May. 14, 2014	Apr. 09, 2014	Sep. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Apr. 19, 2014
Reverse stock split				1-for-10 reverse stock split
Common stock, shares authorized				900,000,000					90,000,000				90,000,000	90,000,000	90,000,000	90,000,000
Number of reverse stock split authorized shares decreased ratably shares of common stock				90,000,000
Preferred stock, shares authorized									10,000,000				10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock, par value									$ 0.001				$ 0.001	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares issued									4,351,442				4,351,442	5,850,000	5,850,000	5,850,000
Preferred stock, shares outstanding									4,351,442				4,351,442	5,850,000	5,850,000	5,850,000
Percentage of equity beneficial ownership									33.34%				33.34%				100.00%
Common stock, shares issued									13,762,705				13,762,705	5,875,640	5,875,640	5,875,640
Common stock, shares outstanding									13,762,705				13,762,705	5,875,640	5,875,640	5,875,640
Common stock, par value									$ 0.001				$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock issued for professional services, value													$ 224,012		$ 30,000
Common stock issued for professional services, shares															25,000
Issuance of common stock, shares							4,420,000			40,000
Proceeds from issueane of common stock							$ 2,210,000								$ 2,210,000
Shares issued of common stock for compensation expense										12,500				105,500	1,500,000
Stock option compensation expense										$ 23,063					$ 67,500
Shares issued in exercise of stock option						2,881						1,000			(1,000)
Stock option exercise price per share		$ 0.33	$ 0.40			$ 3.30						$ 3.30			$ (3.30)
Proceeds from stock option exercised						$ 9,506						$ 3,300	$ 9,506		$ 3,300
Stock compensation expense		$ 8,186	$ 4,972								$ 845,540
Warrants exercise price per share									$ 0.36				$ 0.36
Common stock cancelled during period										75,000
Vesting Period [Member]
Stock compensation expense															$ 92,788
Vesting of Prior Period Awards [Member]
Stock compensation expense										$ 23,063					$ 101,188
Unrelated Party [Member]
Common stock issued for professional services, shares																20,965
Issuances for Vesting Portion Two [Member]
Stock compensation expense											114,083
Vesting of Prior Period Awards [Member]
Stock compensation expense											$ 68,333
Minimum [Member]
Warrants exercise price per share											$ 0.40
Maximum [Member]
Warrants exercise price per share											$ 0.85
Non-Plan Options [Member]
Debt instruments cancelled during the period											1,219,589
Plan Options [Member]
Debt instruments cancelled during the period											1,110,000
Series A Preferred Stock [Member]
Reverse split stock conversion price per share					$ 0.20
Stock conversion price per share					$ 0.02
Common Stock One [Member]
Issuance of common stock, shares											160,000
Shares issued in exercise of stock option											2,881
Stock option exercise price per share											$ 3.30
Proceeds from stock option exercised											$ 9,506
Securities Purchase Agreements [Member]
Preferred stock, shares issued								6,000,000
Money paid by investors from subscription and advances made								$ 6,000,000
Securities Purchase Agreement [Member]
Stock conversion price per share								$ 0.02
Stock conversion description								Shares of Series A Preferred were initially convertible into common stock based on a conversion formula equal to the price per share ($1.00) divided by a conversion price equal to the lesser of (A) $0.02 and (B) seventy percent (70%) of the average of the three (3) lowest daily volume weighted average prices (“VWAPs”) occurring during the twenty (20) consecutive trading days immediately preceding the applicable conversion date on which the Holder elects to convert any shares of Series A Preferred.
Percentage of purchase price plus all accrued but unpaid dividends								100.00%
Securities Purchase Agreement [Member] | Series A Preferred Stock [Member]
Stock conversion price per share								$ 1
Series A Convertible Preferred Stock [Member]
Preferred stock, shares designated									6,000,000				6,000,000
Series A Preferred Stock [Member]
Preferred stock, shares issued									4,351,442				4,351,442
Preferred stock, shares outstanding									4,351,442				4,351,442
Preferred stock conversion into common stock									21,757,210
Percentage of equity beneficial ownership									4.99%				4.99%
Convertible Preferred Stock One [Member]
Preferred stock, shares outstanding									1,498,558				1,498,558	150,000	150,000	150,000
Preferred stock conversion into common stock													7,721,685		750,000
Restricted Common Stock [Member]
Common stock issued for professional services, value	$ 25,000
Common stock issued for professional services, shares	5,887
Warrant [Member]
Debt instruments cancelled during the period											500,000
Warrant [Member] | Minimum [Member]
Warrants exercise price per share									$ 0.30				$ 0.30
Warrant [Member] | Maximum [Member]
Warrants exercise price per share									$ 0.85				$ 0.85

Common Stock Options (Details N

Common Stock Options (Details Narrative) - USD ($)	Jun. 19, 2015	Jun. 01, 2015	Dec. 31, 2014	Oct. 20, 2014	May. 20, 2014	Mar. 05, 2012	Mar. 31, 2015	Dec. 31, 2014	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Number of shares granted under compensation plan										1,410,000	401,530
Maximum date to exercise the option	Jun. 19, 2025	Jun. 1, 2025
Stock option exercise price per share	$ 0.33	$ 0.40		$ 3.30					$ 3.30		$ (3.30)
Volatility rate	237.00%	247.00%								254.00%	104.00%
Value of call option per share	$ 0.3274	$ 0.3978
Value of option	$ 32,744	$ 79,552
Stock compensation expense	$ 8,186	$ 4,972						$ 845,540
Shares cancelled during period							75,000
Warrants exercise price range per share										$ 0.36
Shares issued in exercise of stock option				2,881					1,000		(1,000)
Proceeds from stock option exercised				$ 9,506					$ 3,300	$ 9,506	$ 3,300
Minimum [Member]
Warrants exercise price range per share			$ 0.40					$ 0.40
Maximum [Member]
Warrants exercise price range per share			0.85					$ 0.85
Non-Plan Options [Member]
Shares cancelled during period								1,219,589
Plan Options [Member]
Stock option exercise price per share										$ 0.42	$ 0.21
Shares cancelled during period								1,110,000
Amortization of common stock options										$ 663,626	$ 49,325
Options exercise price description										these options in the aggregate had no intrinsic value as the per share market price of $0.20 of the Company’s common stock as of such date was less than the weighted-average exercise price of these options of $0.43.
Warrant [Member]
Volatility rate										257.00%	0.00%
Shares cancelled during period								500,000
Non-Plan Options Two [Member]
Number of shares issued under stock plan								100,000
Number of shares granted under compensation plan								200,000
Stock option exercise price per share								$ 0.85
Stock compensation expense								$ 82,826
Shares cancelled during period								200,000
Vesting of Prior Period Awards [Member]
Stock compensation expense							$ 23,063				$ 101,188
April 15, 2014 [Member]
Stock option exercise price per share			$ 0.20
Shares cancelled during period			300,000
June 1, 2014 [Member]
Stock option exercise price per share			$ 0.50
Shares cancelled during period			100,000
Chief Financial Officer [Member]
Number of shares granted under compensation plan	100,000
Chief Scientist [Member]
Number of shares granted under compensation plan		200,000
2012 Stock Incentive Plan [Member]
Number of shares issued under stock plan						500,000
Change in number if shares issued under stock plan					3,000,000

Common Stock Options - Summary

Common Stock Options - Summary of Common Stock Option Outstanding (Details)	12 Months Ended
	Sep. 30, 2015$ / sharesshares
Equity [Abstract]
Range of Exercise Price, Minimum	$ 0.33
Range of Exercise Price, Maximum	$ 3.30
Number of Options Outstanding | shares	1,413,881
Weighted Average Remaining Contractual Life	3 years 9 months 26 days
Weighted Average Exercise Price	$ 0.43
Number of Shares Exercisable | shares	1,163,881
Weighted Average Exercise Price Exercisable	$ 0.45

Common Stock Options - Schedule

Common Stock Options - Schedule of Option Pricing Model Weighted-average Assumptions Used for Grands Under Fixed Option Plan (Details)	Jun. 19, 2015	Jun. 01, 2015	Sep. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Average risk-free interest rates			1.62%	0.81%
Expected average term			4 years 5 months 27 days	3 years
Volatility	237.00%	247.00%	254.00%	104.00%

Common Stock Options - Summar58

Common Stock Options - Summary of Common Stock Options Activity Outstanding (Details) - $ / shares	Jun. 19, 2015	Jun. 01, 2015	Oct. 20, 2014	Mar. 31, 2015	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Shares Outstanding, Beginning balance						406,762	6,232
Shares, Expired						(402,881)
Shares, Cancelled				75,000
Shares, Granted						1,410,000	401,530
Shares, Exercised			2,881		1,000		(1,000)
Shares Outstanding, Ending balance						1,413,881	406,762
Shares Exercisable						1,163,881
Weighted Average Exercise Price, Outstanding, Beginning						$ 0.30	$ 3.30
Weighted Average Exercise Price, Expired						$ (0.30)
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Granted						$ 0.43	$ 0.30
Weighted Average Exercise Price, Exercised	$ 0.33	$ 0.40	$ 3.30		$ 3.30		(3.30)
Weighted Average Exercise Price, Outstanding, Ending						$ 0.43	$ 0.30
Weighted Average Exercise Price, Exercisable						$ 0.45

Common Stock Warrants (Details

Common Stock Warrants (Details Narrative) - USD ($)	Jun. 19, 2015	Jun. 01, 2015	Dec. 30, 2014	Oct. 20, 2014	Apr. 19, 2014	Mar. 31, 2015	Jun. 30, 2014	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014
Exercise price of common stock	$ 0.33	$ 0.40		$ 3.30			$ 3.30			$ (3.30)
Common stock cancelled during period						75,000
Fair value of warrants weighted average exercise price								$ 0.36
Expenses associated with issuance of warrants					$ 343,533
DigiPath Corp [Member]
Expenses associated with issuance of warrants								$ 343,533
Precentage of ownership in non contorlling interest								100.00%
Consultants [Member]
Number of common stock purchased through issuance of warrants					6,000,000
Exercise price of common stock					$ 0.10
Common Stock Warrants One [Member]
Number of common stock purchased through issuance of warrants									200,000
Exercise price of common stock									$ 0.30
Common stock cancelled during period									200,000
Common Stock Warrants Two [Member]
Number of common stock purchased through issuance of warrants			300,000
Exercise price of common stock			$ 0.40
Common stock cancelled during period			300,000

Common Stock Warrants - Summary

Common Stock Warrants - Summary of Common Stock Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Equity [Abstract]
Range of Exercise Price, Minimum	$ 0.30
Range of Exercise Price, Maximum	$ 0.40
Number of Warrants Outstanding	500,000
Weighted Average Remaining Contractual Life	2 years 3 months
Weighted Average Exercise Price	$ 0.36
Number of Shares Exercisable	500,000
Weighted Average Exercise Price Exercisable	$ 0.36

Common Stock Warrants - Schedul

Common Stock Warrants - Schedule of Warrant Pricing Model Weighted-average Assumptions Used for Grands Under Fixed Option Plan (Details)	Jun. 19, 2015	Jun. 01, 2015	Sep. 30, 2015	Sep. 30, 2014
Average risk-free interest rates			1.62%	0.81%
Average expected life (in years)			4 years 5 months 27 days	3 years
Volatility	237.00%	247.00%	254.00%	104.00%
Warrant [Member]
Average risk-free interest rates			1.64%	0.00%
Average expected life (in years)			3 years	0 years
Volatility			257.00%	0.00%

Common Stock Warrants - Summa62

Common Stock Warrants - Summary of Common Stock Warrants Activity Outstanding (Details) - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Equity [Abstract]
Shares Outstanding, Beginning balance
Shares, Expired
Shares, Cancelled
Shares, Granted	500,000
Shares, Exercised
Shares Outstanding, Ending balance	500,000
Shares Exercisable	500,000
Weighted Average Exercise Price, Outstanding, Beginning
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Granted	$ 0.36
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Outstanding, Ending	$ 0.36
Weighted Average Exercise Price, Exercisable	$ 0.36

Commitments and Contingencies63

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Monthly rent payable	$ 2,616
Operating lease rent	$ 228,616	$ 63,974

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Rental Payment Under Operating Leases (Details)	Sep. 30, 2015USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,016	$ 24,028
2,017	196,673
2,018	204,540
2,019	212,722
2,020	388,015
Total	$ 1,025,978

Income Tax (Details Narrative)

Income Tax (Details Narrative)	12 Months Ended
	Sep. 30, 2015USD ($)
Income Tax Disclosure [Abstract]
Provision for income taxes
Net operating loss carry forwards	$ 6,652,500
Operating loss expiration year	2,031

Income Tax - Schedule of Effect

Income Tax - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	35.00%	34.00%
State income taxes	3.95%	6.90%
Change in valuation allowance	(38.95%)	(40.90%)
Net effective income tax rate	0.00%	0.00%

Income Tax - Schedule of Deferr

Income Tax - Schedule of Deferred Tax Asset (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 2,328,375	$ 1,433,582
Net deferred tax assets before valuation allowance	2,328,375	1,433,582
Less: Valuation allowance	$ (2,328,375)	$ (1,433,582)
Net deferred tax assets

Segment Operating Results (Deta

Segment Operating Results (Details Narrative)	12 Months Ended
	Sep. 30, 2015Segment
Segment Reporting [Abstract]
Number of operating segments	2

Segment Operating Results - Sch

Segment Operating Results - Schedule of Segment Reporting (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Revenues	$ 16,084	$ 54,941
Gross profit (loss)	(69,467)	25,669
Operating expenses	3,371,987	2,361,776
Loss from operations	(3,441,454)	(2,336,107)
Net loss	(4,332,329)	$ (2,832,202)
Cannabis [Member]
Revenues	16,084
Cost of sales	85,551
Gross profit (loss)	(69,467)
Operating expenses	(3,371,070)	$ (2,323,899)
Loss from operations	(3,440,537)	$ (2,323,899)
Other income (expense)	(273,220)
Net loss	(3,713,757)	$ (2,323,899)
Microscopy [Member]
Revenues	395,718	485,870
Cost of sales	360,652	297,529
Gross profit (loss)	35,066	188,341
Operating expenses	(654,001)	(685,008)
Loss from operations	(618,935)	(496,667)
Other income (expense)	363	(11,636)
Net loss	$ (618,572)	$ (508,303)

Segment Operating Results - S70

Segment Operating Results - Schedule of Segment Operating Results Net Assets (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Corporate [Member]
Net assets	$ 362,513	$ 3,907,777
Cannabis [Member]
Net assets	1,470,902	1,017,680
Microscopy [Member]
Net assets	$ 182,299	$ 561,442

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Dec. 21, 2015	Nov. 23, 2015	Nov. 20, 2015	Oct. 29, 2015	Oct. 08, 2015	Oct. 01, 2015	Jun. 19, 2015	Jun. 01, 2015	Oct. 20, 2014	May. 14, 2014	Mar. 31, 2015	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Apr. 19, 2014
Common stock issued for services, shares														25,000
Warrants exercise price per share													$ 0.36
Stock option exercise price per share							$ 0.33	$ 0.40	$ 3.30			$ 3.30		$ (3.30)
Fair value assumption of volatility rate							237.00%	247.00%					254.00%	104.00%
Fair value of stock option													$ 224,012	$ 298,813
Number of common stock shares issued during the period										4,420,000	40,000
Percentage of outstanding shares of common stock													33.34%			100.00%
Maximum [Member]
Warrants exercise price per share															$ 0.85
Minimum [Member]
Warrants exercise price per share															$ 0.40
Subsequent Event [Member]
Number of common stock shares sold during the period	166,667	100,000
Number of warrants units sold during the period	166,667	100,000
Warrants exercise price per share	$ 0.30	$ 0.40
Warrants period	36 months	36 months
Proceeds from sale of common stock	$ 25,000	$ 20,000
Proceeds from sale of warrants	$ 25,000	$ 20,000
Fair value assumption of call option value			$ 0.1734
Subsequent Event [Member] | Series A Preferred Stock [Member]
Number of converted shares of convertible preferred stock, shares				100,000	120,000
Number of shares converted into common stock				500,000	600,000
Number of preferred stock shares cancellation during						60,000
Subsequent Event [Member] | Joseph Bianco [Member]
Agreement initial term		15 months
Monthly fees		$ 4,000
Deferred fee		$ 2,000
Common stock issued for services, shares		500,000
Subsequent Event [Member] | Board of Directors [Member]
Number of common stock options granted fully vested shares			500,000
Options exercisable period			3 years
Stock option exercise price per share			$ 0.181
Fair value assumption of volatility rate			234.00%
Fair value of stock option			$ 86,708
Subsequent Event [Member] | Steven D. Barbee [Member]
Number of warrants purchase of common stock shares during the period						3,000,000
Indebtedness owned amount						$ 18,000
Subsequent Event [Member] | Steven D. Barbee [Member] | Maximum [Member]
Warrants exercise price per share						$ 0.10
Subsequent Event [Member] | Steven D. Barbee [Member] | Minimum [Member]
Warrants exercise price per share						$ 0.0333333
Subsequent Event [Member] | Third Party [Member]
Number of warrants purchase of common stock shares during the period						3,000,000
Number of common stock shares issued during the period						3,000,000
Number of common stock purchase value during the period						$ 100,000
Number of preferred stock shares surrender during the period						60,000
Percentage of outstanding shares of common stock						34.00%